UBS Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2023
Q3
Sell
-39,027
Closed -$3.98M 8927
2023
Q2
$3.98M Buy
39,027
+21,283
+120% +$2.17M ﹤0.01% 2090
2023
Q1
$1.61M Buy
17,744
+15,259
+614% +$1.39M ﹤0.01% 2783
2022
Q4
$94.4K Sell
2,485
-1,273
-34% -$48.4K ﹤0.01% 5039
2022
Q3
$94K Buy
3,758
+1,200
+47% +$30K ﹤0.01% 4709
2022
Q2
$78K Buy
2,558
+759
+42% +$23.1K ﹤0.01% 4607
2022
Q1
$59K Sell
1,799
-1,759
-49% -$57.7K ﹤0.01% 5323
2021
Q4
$93K Sell
3,558
-2,614
-42% -$68.3K ﹤0.01% 5305
2021
Q3
$621K Sell
6,172
-1,207
-16% -$121K ﹤0.01% 3587
2021
Q2
$1.04M Buy
7,379
+875
+13% +$124K ﹤0.01% 3214
2021
Q1
$648K Sell
6,504
-9,333
-59% -$930K ﹤0.01% 3739
2020
Q4
$1.96M Sell
15,837
-23,506
-60% -$2.9M ﹤0.01% 2649
2020
Q3
$3.83M Buy
39,343
+28,122
+251% +$2.74M ﹤0.01% 1905
2020
Q2
$1.75M Buy
11,221
+8,060
+255% +$1.26M ﹤0.01% 2380
2020
Q1
$456K Sell
3,161
-12,375
-80% -$1.79M ﹤0.01% 3296
2019
Q4
$3.18M Buy
15,536
+9,581
+161% +$1.96M ﹤0.01% 2378
2019
Q3
$479K Sell
5,955
-783
-12% -$63K ﹤0.01% 3764
2019
Q2
$636K Sell
6,738
-21,483
-76% -$2.03M ﹤0.01% 3376
2019
Q1
$2.41M Buy
28,221
+738
+3% +$63.1K ﹤0.01% 2296
2018
Q4
$1.54M Buy
27,483
+959
+4% +$53.8K ﹤0.01% 2653
2018
Q3
$2.17M Sell
26,524
-8,521
-24% -$697K ﹤0.01% 2553
2018
Q2
$1.23M Buy
35,045
+15,112
+76% +$529K ﹤0.01% 2908
2018
Q1
$409K Buy
19,933
+16,458
+474% +$338K ﹤0.01% 3586
2017
Q4
$99K Buy
3,475
+1,110
+47% +$31.6K ﹤0.01% 4427
2017
Q3
$73K Sell
2,365
-967
-29% -$29.8K ﹤0.01% 4659
2017
Q2
$105K Buy
3,332
+2,109
+172% +$66.5K ﹤0.01% 4260
2017
Q1
$27K Sell
1,223
-1,265
-51% -$27.9K ﹤0.01% 5033
2016
Q4
$54K Buy
+2,488
New +$54K ﹤0.01% 4863
2016
Q3
Sell
-2,000
Closed -$40K 6901
2016
Q2
$40K Buy
+2,000
New +$40K ﹤0.01% 4833